Recombinant adeno-associated viruses (rAAV) are promising candidates as gene vectors, as they transduce non-dividing cells and permit lasting transgene expression in a wide spectrum of tissues. In this paper, we describe a robust procedure for the high throughput production, screening and characterization of rAAV vectors. The technology includes the production of rAAV from rapid small scale plasmid preparations and the analysis of virus productivity (physical and infectious particles) and activity (transgene expression, replication). rAAV are produced by triple transfection (rAAV plasmid and AAV-and adenovirus (Ad)-helper plasmids) on Keywords: AAV production; AAV analysis; high throughput Gene therapy vectors are being actively developed as biotechnological drugs based on natural viruses, mostly murine and human retroviruses, adenoviruses (Ad) and adeno-associated viruses (AAV).
Gene therapy vectors are being actively developed as biotechnological drugs based on natural viruses, mostly murine and human retroviruses, adenoviruses (Ad) and adeno-associated viruses (AAV). 1 ,2 Yet, progresses in gene therapy are still limited by the development and availability of new gene transfer vectors and vector structures, suitable for biological efficacy and toxicity studies.
High throughput technology is invading a number of diverse fields in biology, whenever the efficient processing and accurate analysis of large numbers of samples is a rate-limiting step for further developments. [3] [4] [5] [6] [7] [8] [9] Undoubtedly, the field of gene therapy could greatly benefit as well from high throughput approaches. The availability of high throughput procedures suitable for the screening and analysis of large numbers of vectors would be useful for the genetic study of the key elements involved (1) vector backbone architecture; (2) trans-complementing helper functions; (3) regulatable and tissuespecific promoters; and (4) analysis of transgenes and genomic sequences.
In the last few years, rAAV have shown to be promising candidates for a number of gene therapy applications. 10, 11 rAAV transduce non-dividing cells and ensure a persistent transgene expression in a wide spectrum of tissues. [12] [13] [14] [15] [16] [17] [18] We have chosen rAAV as a model for the development of the technology reported in this paper. We describe a procedure for the production, screening and analysis of rAAV out of rapid small scale plasmid DNA preparations (minipreps), that is automation ready. 293 human embryo kidney (HEK) cells. The titers of physical and infectious particles are obtained by dot blot hybridization and by a serial dilution assay, followed by either dot blot hybridization or real-time PCR, respectively. rAAV can be produced and characterized from plasmid mixtures containing as little as 1/100 productive molecules. Experiments on rAAV replication kinetics and Ad helper functions are discussed. All steps are performed in 96-well microtiter plates. The process is reproducible, high throughput, linear and ready for automation. Gene Therapy (2000) 7, 924-929.
In order to obtain a sensitive and reproducible tool for the analysis of small amounts of rAAV, we designed a serial dilution replication assay (dRA). This dRA assay is a modification of the RCA (replication center assay) test [19] [20] and the dot assay 3 previously reported. Briefly, rep-cap trans-complementing (HeLa rep-cap32) cells were infected in 96-well plates with serial dilutions of the rAAV preparations, lysed in situ and either blotted and hybridized with a transgene-specific probe or amplified by real-time PCR using transgene-specific primers. The intensity of the signals obtained was a function of the total number of rAAV genomes inside the infected cells. The experimental points were fitted to a polynomial curve to obtain the titer of the rAAV preparation. Figure 1 shows a typical dRA analysis of a rAAV preparation where rAAV genomes were detected and quantified by dot blot hybridization. Seventy-three dilution points were tested in order to define the shape of the curve fitting the data. Our routine procedure for dRA currently includes only 12-30 dilution points, enough to derive a polynomial curve without significantly affecting titer calculations. Titers were obtained from the polynomial non-linear regression curve fitting the data (insert in Figure 1) .
The drop in the number of replicating rAAV genomes observed at low dilutions (10 −4 ) (see Figure 1 ) may be attributed to a toxic effect on AAV replication caused by the high MOI (MOI = 500) of rAAV infecting the reporter cells.
In all the figures throughout the paper, the intensity of the dot blots has been directly used as the number of genomes (expressed in arbitrary units). For that, the assumption was made that the intensity contributed to the dot by the individual replication centers (cells 
infectious particles/ml. A computer program has been developed for the calculation of titers. It allows for the iterative fitting of the experimental curves with a tangential hyperbole function (of the type f(x) = a1 + a2 th(a3 x + a4), where x is measured by the log (1000/dilution) and f(x) by the log(1/intensity)). This program is available at Généthon III upon request.
undergoing vector replication) are equivalent to each other. To test this assumption we performed five independent replication center assays (RCA) experiments and measured the intensity and the area of 197 individual spots, obtained at different rAAV dilutions points. In the RCA test, the infected cells are spread out on filter membranes before hybridization what allows for the scoring of individual cells undergoing vector replication. Results (not shown) indicate that the ratio intensity/area (indicative of the replication rate) was equivalent for all 197 individual spots analyzed regardless of the amount (dilution) of rAAV used. This observation suggests that the contribution of the individual replication centers to the dot in the dRA experiments was equivalent, and then that the dot intensity can be used as a direct indicator of the number of genomes, expressed in arbitrary units. To validate the assumption for different rAAV backbones, we compared the pSMD2-GFP 13 and pAAV-lacZ, 19 for the intensity of the individual replication centers generated in RCA experiments. Results (not shown) indicate the absence of significant differences in the specific replication rates (intensity/area ratio per replication center) between the two vectors, thus validating the use of the dot intensity in the dRA tests for the comparison between different vectors. Figure 2 shows the comparison of dot blot hybridization and real-time PCR 21 for the detection and quantification of the rAAV genomes in the dRA assay. Dilutions of the same preparation were used for infection and detection of rAAV by both methods. As seen in the Figure, dRA plots elicit the same sigmoidal profile in both cases, although real-time PCR appears to be at least 100-fold more sensitive.
Equipped with a sensitive assay for the analysis of small amounts of infectious rAAV we next down-scaled the production of rAAV in single wells in 96-well microtiter plates. No significant difference (P Ͻ 0.5) was observed in the productivity of rAAV (expressed as Figure 1 (Figure 3) . The titers of infectious particles produced in single wells were lower than those obtained in 10 cm dishes (Figure 1) , as expected on the basis of the productivity of infectious particles per cell, that remains unchanged in the two systems.
The use of miniprep plasmid, instead of large scale purified plasmid (maxiprep), to obtain rAAV in 96-well plates, would allow increase of the throughput of the overall procedure. Experiments were made to compare the performance of mini-and maxiprep plasmid for rAAV production. plasmid was used for the transfection step. The DNA used for transfection can be obtained from bacteria grown in single wells in 96-well microtiter plates, which makes the process useful for the analysis of large numbers of plasmids. Plasmid dilution and mixing experiments were performed in order to address the question of whether the presence of non-relevant plasmids at the transfection step would interfere with the production and analysis of the rAAV. Decreasing amounts of pAAV-lacZ, (from 3.5 × 10 9 to 3.5 × 10 6 DNA molecules per well), in the presence of a constant amount of pAAV-GFP (3.5 × 10 9 DNA molecules) were tested. rAAV were produced by co-transfection (with the four plasmids) in single 96-wells. Figure 4a shows a dRA plot obtained by infection of HeLa rep-cap cells with the resulting rAAV stock (a mixture of rAAV-lacZ and rAAV-GFP), and the detection of only the rAAV-lacZ genomes. The amount of transfecting rAAV plasmid used in single wells can be reduced by a factor of 100 before the limit of detection of the dRA assay is reached. The number of transducing particles of rAAV-lacZ produced, measured as lacZ forming units, closely correlated with the titer of infectious particles obtained by dRA assay (Figure 4b ). In addition, the number of transducing particles of rAAV-GFP present in the rAAV stocks analyzed in Figure 4a , was not affected by the amount of pAAV-lacZ at the transfection step, nor by that of rAAV-lacZ virus at the analysis (dRA and Lfu tests) steps. Taken together, data in Figure 4 indicate that specific rAAV molecules can be detected and characterized, even when present in ratios of 1 to 100 in mixtures of non-relevant molecules.
dRA assays were performed to test the relative efficiency of two rAAV plasmids expressing the lacZ gene, and expectedly differing in their capacity for the production of infectious rAAV: pAB11-⌬ITR and pAAVlacZ. rAAV were produced in single 96-wells as described above. pAB11-⌬ITR carries a mutation in one of the AAV-ITR, which is expected to affect AAV DNA replication and consequently the production of active vector particles. Figure 5 shows the dRA plots obtained by the analysis of the rAAV produced by either pAB11-⌬ITR or pAAV-lacZ. As expected, the deletion in the ITR strongly affected rAAV productivity.
The high throughput process described in Figures 1-5 , can be used whenever handling high numbers of samples under standardized conditions is necessary. Figures 6  and 7 show a series of experiments where rAAV replication was studied with the dRA system, under various conditions (increasing time-points after infection and different Ad types).
For a kinetic study (Figure 6 ), rAAV replication was allowed to continue for increasing time points, from 0 to 72 h after infection of the HeLa rep-cap32 cells. dRA plots from the kinetic data, shown in Figure 6a , suggest that replication of rAAV includes three phases taking place in the dilution intervals between 10 −11 to 10 −9 ; 10 −9 to 10 −5
and 10 −5 to 10 −3 , respectively. The number of genomes increases over time during phase I, indicating that phase I represents an active biological process. That process, however, appears to be independent from the rAAV input level since the number of genomes remains unchanged regardless of the rAAV input. The process involved in phase I appears to be of high affinity (sensitive to low inputs) and low capacity (already saturated at dilution of 10 −11 ). Figure 6b shows the number of rAAV genomes accumulated over time in phase I. The plateau observed scores the maximal size of the pool of rAAV molecules generated in this phase.
At rAAV dilutions of 10 −9 , a different phenomenon seems to be triggered for the further replication of the rAAV genomes (phase II). Phase II is the most productive phase of the replication process. This phase is characterized by (2 logs) lower affinity than phase I and higher capacity (not saturated up to dilutions of 10
−5
). Phase III takes place at very high rAAV inputs and seems to repGene Therapy resent the saturation of the system. On the contrary, a toxic effect on rAAV replication was observed in phase III, as there is a drop in the number of rAAV genomes as the rAAV input and the time after infection increase. At very high dilutions 10 −9 to 10 −12 very few infectious particles are being plated. However, these particles are undergoing a productive infection, they are not blocked at entry or second strand synthesis, they should be replicating the recombinant genome and packaging 10 6 rAAV molecules per cell. In phase II (the middle dilutions 10 −9 to 10 −5
) the number of cells infected with virus has not been maximized. Once this has taken place, the amount of virus produced cannot be increased, each cell is producing 10 6 rAAV genomes. In phase III, there are no further increases in the numbers of rAAV genomes. A toxic effect on rAAV replication appears to happen due to the very high number of input virus per cell.
In the presence of increasing MOIs of the co-infecting wtAd5, the number of rAAV molecules replicated per cell increases as a function of the MOI of helper wtAd5 (data not shown). In addition, the initial affinity in phase II was a function of the helper Ad MOI, as the higher the Ad5 MOI the lower the rAAV input at which phase II is triggered. Figure 7 shows dRA plots obtained for different helper Ad types, including human wtAd5 (Ad5), wtAd2 (Ad2) and Ad5ts7001 (ts-Ad) and canine adenoviruses 1 (CAV-1) and 2 (CAV-2). It can be seen that Ad5, Ad2 and tsAd are equally efficient for helping the replication of rAAV in these cells at 37°C. On the contrary, both canine adenoviruses CAV-1 and CAV-2 were less efficient for helping rAAV replication.
The process described in this paper is aimed to be used for the high throughput production and screening of rAAV. The process constitutes, in principle, the basis for a high throughput procedure for the screening of large libraries of vectors constructs.
The approach described in this paper for the high throughput production, screening and analysis of rAAV, can be extended to other virus vectors of common use in gene therapy, such as retroviruses, adenoviruses and herpes viruses, for which production methods other than transfection are used.
In this paper, we describe an efficient and accurate procedure for the production, screening and analysis of rAAV in a 96-well microtiter plates format. Production of rAAV is performed by triple transfection of 293 HEK cells with an AAV helper plasmid, an Ad helper plasmid and a rAAV plasmid vector. 22 Under these conditions, rAAV can be produced with efficiencies comparable to those obtained in larger scale systems. The amount of rAAV produced in single individual wells is large enough to allow for further analysis of the virus produced, in terms of titer and biological activity. The global process outlined in Figure 8 is robust, high throughput, linear and can be readily automated.
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